# 2025-06837: New Order Aims to Slash Prescription Drug Costs for Americans 2025-06837, Lowering Drug Prices by Once Again Putting Americans First, is a Federal Register presidential document from Executive Office of the President published 2025-04-18, effective 2025-04-15; PRIA reads it as touching household money (as of 2026-11-04). - Canonical: https://policyrisk.com/federal-register/2025-06837 - As of: 2026-11-04 - Plain-text twin of the page above; the HTML and this file carry the same facts. ## Facts - Document number: 2025-06837 - Title: Lowering Drug Prices by Once Again Putting Americans First - Type: Presidential Document - Agencies: Executive Office of the President - Citation: 90 FR 16441 - Published: 2025-04-18 - Effective: 2025-04-15 - Comments close: not stated - Significant: no - Touches household money: yes - Regulation identifier numbers: none - Last updated: 2026-11-04 ## In one line New Order Aims to Slash Prescription Drug Costs for Americans ## Summary This new order puts Americans first by bringing back strong actions to lower prescription drug prices. It targets drug companies charging U.S. patients more than people in other countries and pushes for cheaper generics, better price transparency, and fairer discounts. These changes aim to save patients money starting now and keep drug costs down for years to come. ## Effects PRIA read - Medicare negotiation guidance update: benefit, medium. Within 60 days of April 15, 2025, the Department of Health and Human Services must propose guidance to improve transparency and prioritization in the Medicare Drug Price Negotiation Program for initial price applicability year 2028 and manufacturer effectuation in 2026–2028. If you have Medicare, t… - Plans to stabilize Medicare Part D premiums: benefit, medium. Within 180 days of April 15, 2025, White House domestic policy staff and HHS will give recommendations on how to stabilize and reduce Medicare Part D premiums. If you are in a Medicare Part D plan, this could affect future premiums and plan choices. - End the "pill penalty" for fair pricing: benefit, medium. The order directs HHS to work with Congress to align how small molecule drugs (pills, tablets) and biological products are treated in the Medicare Drug Price Negotiation Program to end the earlier imposition of price controls on small molecules. If you have Medicare, this seeks to prevent policies… - Payment model for high-cost Medicare drugs: benefit, medium. Within 1 year of April 15, 2025, HHS must develop and implement a rulemaking plan and select a payment model to get better value for high-cost prescription drugs and biological products covered by Medicare. If you have Medicare, this could change how expensive drugs are paid for and how much Medica… - Survey hospital drug acquisition costs: benefit, low. Within 180 days of April 15, 2025, HHS must publish a plan to survey hospital acquisition costs for outpatient drugs and then consider payment adjustments to better align Medicare payment with acquisition cost, subject to budget neutrality rules. This could affect Medicare payment rates for drugs a… - Medicaid rebate and payment recommendations: benefit, medium. Within 180 days of April 15, 2025, OMB and White House policy staff, in coordination with HHS, must recommend ways to ensure manufacturers pay accurate Medicaid drug rebates, promote innovation in Medicaid drug payment methods, and link payments to value to help States manage drug spending. If you… - Low-cost insulin and epinephrine at health centers: benefit, medium. Within 90 days of April 15, 2025, future federal grants under section 330(e) must be conditioned so health centers make insulin and injectable epinephrine available at or below the grantee's 340B discounted price (plus a minimal administration fee) to people with low incomes, high cost-sharing for… - Accelerate generics, biosimilars, OTC switches: benefit, medium. Within 180 days of April 15, 2025, the FDA must issue a report with administrative and legislative recommendations to speed approval of generics, biosimilars, combination products, and second-in-class drugs, and to improve the process for switching prescription drugs to over-the-counter. This aims… - Streamline drug importation program for States: benefit, medium. Within 90 days of April 15, 2025, the FDA must take steps to streamline and improve the drug Importation Program under section 804 of the Food, Drug, and Cosmetic Act to make it easier for States to obtain approval while maintaining safety and quality. This aims to let States bring in lower-cost im… - Prevent costly shifts to hospital outpatient care: benefit, low. Within 180 days of April 15, 2025, HHS shall evaluate and, if appropriate, propose regulations to ensure Medicare payment rules do not encourage moving drug administration from less costly physician offices to more expensive hospital outpatient departments. If you have Medicare, this could help avo… - PBM fee disclosure for employer plans: benefit, low. Within 180 days of April 15, 2025, the Department of Labor must propose regulations under ERISA section 408(b)(2)(B) to improve employer-plan fiduciary transparency into direct and indirect compensation received by pharmacy benefit managers. If you get insurance through your employer, this may incr… - Public hearings to curb pharma anti‑competitive acts: benefit, low. Within 180 days of April 15, 2025, HHS will hold public listening sessions with the Department of Justice, Department of Commerce, and the Federal Trade Commission and issue a report with recommendations to reduce anti-competitive behavior by drug manufacturers. This aims to protect competition and… - Reevaluate middlemen in drug supply chain: benefit, medium. Within 90 days of April 15, 2025, White House policy staff shall provide recommendations on promoting a more competitive, efficient, transparent, and resilient pharmaceutical value chain to deliver lower drug prices for Americans. This aims to address the role of intermediaries that can affect the… ## Related documents - [2026-22385](https://policyrisk.com/federal-register/2026-22385): Adjusting Imports of Robotics, Industrial Machinery, and Their Parts and Components Into the United States, 2026-11-02 - [2026-22292](https://policyrisk.com/federal-register/2026-22292): Further Modifying the Scope of Products of Canada Subject to the Additional Duties Imposed To Offset Canadian Discrimination Against the Co…, 2026-10-30 - [2026-22051](https://policyrisk.com/federal-register/2026-22051): Decreasing Housing Costs for the American People, 2026-10-28 - [2026-22052](https://policyrisk.com/federal-register/2026-22052): Presidential Determination Pursuant to Section 303 of the Defense Production Act of 1950, as Amended, on Domestic Petroleum Production, Ref…, 2026-10-28 - [2026-22049](https://policyrisk.com/federal-register/2026-22049): Adjusting Imports of Wind Turbines and Their Parts and Components Into the United States, 2026-10-28 - [2026-22050](https://policyrisk.com/federal-register/2026-22050): National Seafood Month, 2026, 2026-10-28 ## Sources - [2025-06837 on federalregister.gov](https://www.federalregister.gov/documents/2025/04/18/2025-06837/lowering-drug-prices-by-once-again-putting-americans-first) - [2025-06837 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-04-18/pdf/2025-06837.pdf) ## Related - [Previous: 2025-06836, Ensuring National Security and Economic Resilience Through Section 232 Actions…](https://policyrisk.com/federal-register/2025-06836) - [Next: 2025-06838, Restoring Common Sense to Federal Office Space Management](https://policyrisk.com/federal-register/2025-06838) - [All Federal Register documents](https://policyrisk.com/federal-register) Source: PRIA, https://policyrisk.com/federal-register/2025-06837 (as of 2026-11-04).